Gritstone gets $21mm through Series C ahead of IPO

19:40 EDT 27 Aug 2018 | Elsevier Business Intelligence

Gritstone Oncology Inc. (cancer immunotherapies) raised $21mm through its Series C round, including a $10mm investment from n...

Original Article: Gritstone gets $21mm through Series C ahead of IPO


More From BioPortfolio on "Gritstone gets $21mm through Series C ahead of IPO"

Quick Search


Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...